Revelation Biosciences Posts $5.92 GAAP Loss Per Share in Q3 2026
Photo: TokenPost
Revelation Biosciences, Inc. (REVB) posted a GAAP loss of $5.92 per share for the third quarter of 2026. The company had $9.1 million in cash and cash equivalents at quarter-end. Cash and cash equivalents totaled $9.1 million as of Sept. 30, 2026, compared with $10.7 million on Dec. 31, 2025. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
